Claim 1 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 2 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 3 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 4 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 5 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 6 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 7 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 8 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 9 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 10 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 11 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 12 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 13 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 14 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 15 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 16 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 17 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 18 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 19 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 20 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 21 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 22 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 23 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 24 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 25 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 26 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 27 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 28 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 29 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 30 benchmark comparison supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL outperforms existing CRISPRa systems in vitro and in vivo.
Claim 31 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 32 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 33 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 34 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 35 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 36 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 37 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 38 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 39 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 40 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 41 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 42 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 43 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 44 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 45 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 46 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 47 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 48 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 49 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 50 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 51 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 52 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 53 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 54 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 55 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 56 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 57 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 58 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 59 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 60 mechanism supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL recruits transactivators through MS2 coat protein binding to MS2 aptamers embedded within the sgRNA scaffold.
Claim 61 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 62 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 63 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 64 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 65 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 66 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 67 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 68 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 69 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 70 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 71 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 72 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 73 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 74 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 75 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 76 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 77 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 78 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 79 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 80 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 81 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 82 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 83 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 84 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 85 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 86 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 87 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 88 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 89 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 90 performance supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL induces over 100,000-fold activation of endogenous genes.
gene activation fold change 100000
Claim 91 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 92 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 93 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 94 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 95 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 96 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 97 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 98 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 99 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 100 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 101 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 102 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 103 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 104 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 105 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 106 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 107 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 108 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 109 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 110 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 111 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 112 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 113 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 114 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 115 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 116 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 117 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 118 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 119 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 120 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review AAV-delivered HEAL targeting interleukin 10 alleviates acute kidney injury in mice.
Claim 121 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 122 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 123 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 124 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 125 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 126 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 127 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 128 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 129 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 130 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 131 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 132 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 133 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 134 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 135 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 136 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 137 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 138 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 139 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 140 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 141 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 142 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 143 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 144 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 145 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 146 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 147 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 148 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 149 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 150 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 151 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 152 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 153 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 154 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 155 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 156 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 157 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 158 therapeutic application supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL-mediated activation of thymic stromal lymphopoietin reduces body weight in obese mice.
Claim 159 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 160 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 161 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 162 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 163 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 164 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 165 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 166 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 167 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 168 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 169 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 170 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 171 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 172 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 173 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 174 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 175 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 176 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 177 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 178 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 179 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 180 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 181 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 182 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 183 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 184 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 185 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 186 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 187 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 188 tool introduction supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review HEAL is a high-efficiency dCas12f-based CRISPRa system for endogenous gene activation.
Claim 189 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 190 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 191 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 192 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 193 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 194 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 195 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 196 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 197 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 198 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 199 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 200 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 201 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 202 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 203 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 204 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 205 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 206 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 207 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 208 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 209 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 210 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 211 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 212 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 213 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 214 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 215 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 216 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 217 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 218 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 219 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 220 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 221 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 222 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 223 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 224 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 225 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 226 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review ChemHEAL is a small-molecule-inducible HEAL variant for remote and precise transcriptional control.
Claim 227 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 228 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 229 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 230 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 231 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 232 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 233 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 234 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 235 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 236 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 237 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 238 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 239 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 240 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 241 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 242 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 243 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 244 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 245 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 246 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 247 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 248 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 249 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 250 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 251 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 252 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 253 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 254 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 255 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.
Claim 256 tool variant supports 2026 Source 1 A compact and inducible dCas12f-based CRISPRa platform for programmable in vivo gene activation. needs review OptoHEAL is a red-light-inducible HEAL variant for remote and precise transcriptional control.